Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; dilute hydrochloric acid; water for injections; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 623.4 mg/ml - injection - excipient ingredients: dilute hydrochloric acid; water for injections; trometamol; sodium calcium edetate; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 311.7 mg/ml - injection - excipient ingredients: trometamol; water for injections; sodium calcium edetate; dilute hydrochloric acid; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 498.72 mg/ml - injection, solution - excipient ingredients: water for injections; trometamol; sodium calcium edetate; dilute hydrochloric acid; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerized tomography. indications as at 6th july 2001: ultravist is indicated for all angiographic and urographic examinations and for contrast enhancements in computerised tomography. ultravist 240 is additionally indicated for lumbar myelography in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate; dilute hydrochloric acid; trometamol; sodium hydroxide - all angiographic and urographic examinations and for contrast enhancement in computerised tomography.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - iopromide, quantity: 768.86 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; sodium calcium edetate; trometamol; water for injections; sodium hydroxide - ultravist is indicated for all angiographic and urographic examinations and for contrast enhancement in computerised tomography.,ultravist 300 or 370 is indicated for use in contrast-enhanced mammography (cem) in adults, to visualise known or suspected lesions of the breast as an adjunct to mammography (with or without ultrasound).

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - iopromide - solution for injection - 300 milligram(s)/millilitre - watersoluble, nephrotropic, low osmolar x-ray contrast media; iopromide

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 498.72 mg/ml equivalent to 240 mg iodine - solution for infusion - 240 mg/ml - active: iopromide 498.72 mg/ml equivalent to 240 mg iodine excipient: hydrochloric acid as 10% solution sodium calcium edetate, hydrate trometamol water for injection - for intravascular use and use in body cavities. contrast enhancement in computerised tomography (ct), arteriography and venography, intravenous/intra-arterial digital subtraction angiography (dsa), intravenous urography, use for ercp, arthrography and examination of other body cavities. ultravist 240: also for intrathecal use. ultravist 370: especially for angiocardiography. ultravist 300/370: not for intrathecal use.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 623 mg/ml equivalent to iodine 300 mg/ml - solution for infusion - 300 mg/ml - active: iopromide 623 mg/ml equivalent to iodine 300 mg/ml excipient: hydrochloric acid as 10% solution sodium calcium edetate trometamol water for injection - for intravascular use and use in body cavities. contrast enhancement in computerised tomography (ct), arteriography and venography, intravenous/intra-arterial digital subtraction angiography (dsa), intravenous urography, use for ercp, arthrography and examination of other body cavities. ultravist 240: also for intrathecal use. ultravist 370: especially for angiocardiography. ultravist 300/370: not for intrathecal use.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - iopromide 769 mg/ml equivalent to iodine 370 mg/ml - solution for infusion - 370 mg/ml - active: iopromide 769 mg/ml equivalent to iodine 370 mg/ml excipient: hydrochloric acid sodium calcium edetate trometamol water for injection - for intravascular use and use in body cavities. contrast enhancement in computerised tomography (ct), arteriography and venography, intravenous/intra-arterial digital subtraction angiography (dsa), intravenous urography, use for ercp, arthrography and examination of other body cavities. ultravist 240: also for intrathecal use. ultravist 370: especially for angiocardiography. ultravist 300/370: not for intrathecal use.